CHICAGO — In patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, chronic kidney disease, or both, the oral formulation ... 15 mL/min/1.73 m 2), missed ...

No­vo Nordisk is go­ing all-in on next-gen­er­a­tion obe­si­ty med­i­cines, and on Fri­day an­nounced a li­cens­ing deal with a Texas biotech to get ac­cess to its … ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity ... its blockbuster glucagon-like ...

Eli Lilly is gearing up for a breakthrough in diabetes and obesity treatment with its upcoming oral GLP-1 drug, orforglipron. In an exclusive conversation with CNBC-TV18’s Shereen Bhan, the company’s ...

with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31% ...

Walgreens is closing two stores in Los Angeles County and another three in Orange County. The stores include a location in Whittier and another in downtown Los Angeles. All told, at least 93 ...